ZLDPY (Zealand Pharma AS) Growth Rank: 5 (As of Sep. 03, 2026) — 29% Below Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ZLDPY Zealand Pharma AS ZLDPY
28 GF Score
Price $8.85
! 7 Warning Signs
View Full Analysis

What is Zealand Pharma AS Growth Rank?

Zealand Pharma AS ZLDPY 28 Growth Rank is 5 as of Sep. 03, 2026, which is 29% below its 10-year median of 7.00. GuruFocus rates ZLDPY with a GF Score™ of 28/100. The stock has 7 warning signs investors should review.

Zealand Pharma AS has the Growth Rank of 5.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Zealand Pharma AS Growth Rank Related Terms

ZLDPY vs VRTX, REGN, MRNA: Growth Rank Comparison

For the Biotechnology subindustry, Zealand Pharma AS's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zealand Pharma AS Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Growth Rank distribution charts can be found below:

* The bar in red indicates where Zealand Pharma AS's Growth Rank falls into.


ZLDPY
28GF Score
Zealand Pharma AS ZLDPY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 5 mean?
Zealand Pharma AS (ZLDPY) has a Growth Rank of 5 as of Sep. 03, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Zealand Pharma AS and its competitors. This is 29% below median its historical median of 7.00. Over the past decade, Zealand Pharma AS's Growth Rank has ranged from 5.00 to 7.00.
Is Zealand Pharma AS's Growth Rank too high?
Zealand Pharma AS's current Growth Rank of 5 is 29% below median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 5.00 to a high of 7.00. Overall, Zealand Pharma AS has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Growth Rank compare to VRTX and REGN?
Zealand Pharma AS's Growth Rank of 5 can be compared against companies in the Biotechnology industry. Historically, Zealand Pharma AS's own Growth Rank has ranged from 5.00 to 7.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Zealand Pharma AS and its competitors. Zealand Pharma AS's current Growth Rank is 5, which is 29% below median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (ZLDPY) has a current Growth Rank of 5. The current Growth Rank is 5, which is 29% below median its 10-year median of 7.00. Zealand Pharma AS's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Zealand Pharma AS (ZLDPY), the current Growth Rank is 5 as of Sep. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zealand Pharma AS Business Description

Address Sydmarken 11, Soborg, DNK, DK-2860
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
28GF Score

Get the complete analysis for ZLDPY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.85
Price